Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.
Schalken
Jack A
JA
Department of Urology, Radboud University Nijmegen Medical Center, Postbus 9101, 6500 HB, Nijmegen, the Netherlands. J.Schalken@uro.umcn.nl